The North America Companion Diagnostics Market would witness market growth of 19.8% CAGR during the forecast period (2019-2025).
Companion Diagnostics is used to determine who would benefit from the treatment and it is useful to identify not only if someone is unable to be cured, but can also detect if a patient shows a tendency of being harmed by the use of specific drugs used to treat them. Technological advances have introduced many modifications to the treatment approach against diseases. Companion diagnostics is associated with a growing need for improved personalized patient treatment that provides health care professionals and their patients a favorable outcome of treatment assurance, as opposed to traditional treatment methods. Companion diagnostics will also have a major effect on the area of oncology therapy.
Targeted therapies have been developed in oncology and other fields and therefore demand for companion diagnostics has risen. Moreover, market growth among end-user industries like pharmaceutical and biotechnology firms is growing, who are willing to introduce new drugs on the market more quickly with lower-cost clinical trials as they have lowered their time and cost.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
- Polymerase chain reaction (PCR)
- Next generation sequencing (NGS)
- In Situ Hybridization and
- Other Technology
- Neurology and
- Other Indications
By Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer and
- Other Cancer Type
- Rest of North America
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free